Results 251 to 260 of about 17,985,271 (268)

CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors

European Journal of Medicinal Chemistry, 2001
Ana Castro, Ana Martinez, Carmen Gil
exaly  

Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present)

Expert Opinion on Therapeutic Patents, 2016
Andres A Trabanco, Peter Buijnsters, Frederik Rombouts   +2 more
exaly  

1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors

Bioorganic and Medicinal Chemistry Letters, 2010
John Walker, Michael J Palmer, Brian R Bond   +2 more
exaly  

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication

Expert Opinion on Investigational Drugs, 2009
Chris T Derk
exaly  

Nitric oxide releasing phosphodiesterase type 5 inhibitor

2020
ALMIRANTE NICOLETTA, BRAMBILLA STEFANIA, STORONI LAURA, IMPAGNATIELLO FRANCESCO, BASTIA ELENA   +4 more
openaire   +2 more sources

The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors

European Urology, 2009
Tobias Kohler
exaly  

Elucidation of Phosphodiesterase Type 5 Inhibitor Mechanism of Action

Journal of Urology, 2013
openaire   +2 more sources

Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential

Bioorganic and Medicinal Chemistry, 2016
Olga Lavrik, Nariman Salakhutdinov
exaly  

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

Neuropharmacology, 1983
H Wachtel
exaly  

Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application

European Urology, 2009
Dimitrios Hatzichristou
exaly